Parametric Portfolio Associates LLC Has $79.20 Million Holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH)

Share on StockTwits

Parametric Portfolio Associates LLC raised its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 3.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 620,183 shares of the medical equipment provider’s stock after buying an additional 21,469 shares during the quarter. Parametric Portfolio Associates LLC owned approximately 0.30% of Zimmer Biomet worth $79,197,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Lindbrook Capital LLC increased its holdings in shares of Zimmer Biomet by 207.6% in the 1st quarter. Lindbrook Capital LLC now owns 203 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 137 shares during the last quarter. Motco grew its stake in Zimmer Biomet by 86.2% during the 1st quarter. Motco now owns 216 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 100 shares during the last quarter. Doyle Wealth Management bought a new position in Zimmer Biomet during the 4th quarter worth $41,000. Pinnacle Bank bought a new position in Zimmer Biomet during the 4th quarter worth $45,000. Finally, Horan Capital Advisors LLC. bought a new position in Zimmer Biomet during the 1st quarter worth $51,000. Institutional investors own 88.55% of the company’s stock.

In other Zimmer Biomet news, insider Sang Yi sold 426 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $114.88, for a total value of $48,938.88. Following the completion of the sale, the insider now owns 1,457 shares in the company, valued at approximately $167,380.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.72% of the stock is currently owned by company insiders.

A number of research analysts have issued reports on the company. Morgan Stanley boosted their price target on Zimmer Biomet from $132.00 to $143.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Evercore ISI upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 price objective for the company in a report on Monday, April 8th. Zacks Investment Research lowered Zimmer Biomet from a “hold” rating to a “sell” rating in a report on Saturday, April 13th. Barclays upped their price objective on Zimmer Biomet from $113.00 to $117.00 and gave the company an “underweight” rating in a report on Monday, April 15th. Finally, Needham & Company LLC upgraded Zimmer Biomet from a “buy” rating to a “strong-buy” rating and upped their price objective for the company from $146.00 to $155.00 in a report on Wednesday, April 24th. Three analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $131.41.

Shares of NYSE ZBH traded up $0.39 during mid-day trading on Tuesday, reaching $118.12. 916,600 shares of the company traded hands, compared to its average volume of 1,219,266. Zimmer Biomet Holdings Inc has a fifty-two week low of $96.99 and a fifty-two week high of $134.55. The firm has a market cap of $24.05 billion, a price-to-earnings ratio of 15.46, a P/E/G ratio of 2.16 and a beta of 1.17. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.97 and a current ratio of 2.00.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Friday, April 26th. The medical equipment provider reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.01. Zimmer Biomet had a positive return on equity of 13.24% and a negative net margin of 3.90%. The firm had revenue of $1.98 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the company earned $1.91 EPS. The firm’s revenue for the quarter was down 2.1% compared to the same quarter last year. As a group, equities research analysts forecast that Zimmer Biomet Holdings Inc will post 7.81 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be given a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.81%. Zimmer Biomet’s dividend payout ratio is currently 12.57%.

TRADEMARK VIOLATION NOTICE: “Parametric Portfolio Associates LLC Has $79.20 Million Holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH)” was first reported by Tech Know Bits and is the property of of Tech Know Bits. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://techknowbits.com/2019/06/18/zimmer-biomet-holdings-inc-zbh-shares-bought-by-parametric-portfolio-associates-llc.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Recommended Story: How much can an individual set aside as a catch-up contribution?

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.